Key result
Elevated plasma PCSK9 levels fail to predict 1-year all-cause mortality in acute coronary syndromes.
Why the study?
The clinical utility of PCSK9 plasma levels to guide treatment and predict outcomes in patients with acute coronary syndromes was unknown.
Do high plasma PCSK9 levels predict all-cause death at 1 year in patients with acute coronary syndromes?
Cohort (n=2,030)
Do high plasma PCSK9 levels predict all-cause death at 1 year in patients with acute coronary syndromes?
Hazard Ratio: 1.13 (95% CI 0.69–1.85)
In patients with acute coronary syndromes, high initial PCSK9 plasma levels are associated with inflammation and hypercholesterolemia but do not predict mortality at 1 year.
No takes yet. Share an insight, caveat, or question.
PCSK9 levels should not inform 1-year mortality risk assessment in ACS; leaves open their utility for predicting LDL target achievement.
Gencer et al. (2015) conducted a cohort in Acute coronary syndromes (ACS) (n=2,030). Plasma PCSK9 levels vs. Lower PCSK9-level tertiles was evaluated on All-cause death (HR 1.13, 95% CI 0.69-1.85). In patients with acute coronary syndromes, upper versus lower tertiles of plasma PCSK9 levels did not predict all-cause mortality at 1 year (HR 1.13; 95% CI 0.69-1.85).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: